Compare Sanofi SA (SNY) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.46 (market cap $296.92M). The key difference: Sanofi SA is far larger — about 320.6× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Sanofi SA pays a 6.01% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| SNY | YMAG | |
|---|---|---|
Market Cap | $95.18B | $296.92M |
Volume | 2,995,646 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $52.34 | $15.68 |
52-Week Low | $39.51 | $10.76 |
Typical Hold Time | 94 Days | 62 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
YMAG trades at $11.49, down 0.69% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation ratios remain unavailable. Recent news highlights ongoing distribution announcements and trading activity, with the stock showing moderate volatility within a tight $11-12 range.
The outlook remains cautiously optimistic given the bullish technical setup and income generation through dividends. However, risks include NAV stability concerns during earnings periods and dependency on underlying option strategies. Investors should weigh the high distribution yield against potential capital volatility in market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
